# Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan

> **NCT03349840** · PHASE4 · TERMINATED · sponsor: **Weill Cornell Medical College in Qatar** · enrollment: 273 (actual)

## Conditions studied

- Type2 Diabetes

## Interventions

- **DRUG:** Insulin Degludec U100
- **DRUG:** Insulin Glargine

## Key facts

- **NCT ID:** NCT03349840
- **Lead sponsor:** Weill Cornell Medical College in Qatar
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-07
- **Primary completion:** 2018-08-03
- **Final completion:** 2018-12-31
- **Target enrollment:** 273 (ACTUAL)
- **Why stopped:** The study was terminated by the IRB and the Institutional Official after the MOPH and WCMQ audits
- **Last updated:** 2020-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03349840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03349840, "Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03349840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*